GeneDx Holdings Corp.

WGS Healthcare Diagnostics & Research

GeneDx Holdings Corp.’s revenue for fiscal 2025 (year ended December 2025) was $427.5 million, up 40.0% from fiscal 2024. In the quarter to June 2026, revenue grew 11.4%, EPS fell 257.9%, free cash flow fell 585.6% and total debt rose 87.4%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

63.60 6.62 −9.43%
Market cap
$2.1B
P/E
0.0×
Fwd P/E
−17.4×
Dividend yield
—
F-score
6/9
Altman Z
7.80
Beneish M
−2.36
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Total current assets
268.29 197.97 182.34 212.62 483.54 174.11 —
Total non-current assets
255.42 221.41 236.42 278.32 70.55 77.53 —
Total Assets
523.71 419.38 418.76 490.94 554.09 251.64 —
Total current liabilities
108.91 54.82 58.82 144.30 101.28 73.44 —
Total non-current liabilities
106.62 119.32 131.92 92.94 64.71 173.81 —
Total liabilities
215.53 174.13 190.74 237.24 165.99 247.25 —
Common Equity (Total)
308.18 245.25 228.02 253.71 388.10 (330.05) —
Shareholders Equity (Total)
308.18 245.25 228.02 253.71 388.10 4.39 —
Total Debt
48.18 51.91 52.69 6.25 11.00 39.75 —

Show all line items

In millions of $ except per-share values · columns are period end dates